Melatonin in COVID-19

Not Applicable

• Conditions: COVID-19.; Clinically-epidemiologically diagnosed COVID-19; U07.2

• Registration Number: IRCT20200922048804N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

mild to moderate patients with COVID-19 who receive Hydroxy chloroquine
Confirmation of the disease is based on CT scan and clinical symptoms and physician diagnosis
Patients 25-65 years

Exclusion Criteria

Patient with depression, COPD, sleep apnea and seizure
Patients with severe kidney problem (eGFR<30 ml/min)
Patients with severe liver problem
Patients who receive fluvoxamine, benzodiazepine or zolpidem
patients who receive drugs that extends QT
Pregnant and breastfeeding mothers
Patients who have allergy to melatonin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Headache. Timepoint: 10-14 days. Method of measurement: COVID-19 questionnaire.;Lung infection. Timepoint: 10-14 days. Method of measurement: CTscan and physician diagnosis.;CRP ( C reactive protein). Timepoint: 10-14 days. Method of measurement: Lab test.;Fever. Timepoint: 10-14days. Method of measurement: questionnaire.;Vomiting. Timepoint: 10-14 days. Method of measurement: Questionnaire.;No smelling. Timepoint: 10-14 days. Method of measurement: questionnaire.;No taste. Timepoint: 10-14 days. Method of measurement: questionnaire.;Cough. Timepoint: 10-14 days. Method of measurement: Questionnaire.;Respiratory distress. Timepoint: 10-14days. Method of measurement: questionnaire.